Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01388
|
|||||
| Drug Name |
Silvestrol
|
|||||
| Synonyms |
Naturally derived compounds (cancer); Naturally derived compounds (cancer), Bristol-Myers Squibb/National Cancer Institute
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Cancer [ICD11: 2A00-2F9Z] | Preclinical | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C34H38O13
|
|||||
| Canonical SMILES |
COC1C(OC(CO1)C(CO)O)OC2=CC3=C(C(=C2)OC)C4(C(C(C(C4(O3)C5=CC=C(C=C5)OC)C6=CC=CC=C6)C(=O)OC)O)O
|
|||||
| InChI |
InChI=1S/C34H38O13/c1-40-20-12-10-19(11-13-20)34-27(18-8-6-5-7-9-18)26(30(38)42-3)29(37)33(34,39)28-23(41-2)14-21(15-24(28)47-34)45-32-31(43-4)44-17-25(46-32)22(36)16-35/h5-15,22,25-27,29,31-32,35-37,39H,16-17H2,1-4H3/t22-,25-,26-,27-,29-,31-,32-,33+,34+/m1/s1
|
|||||
| InChIKey |
GVKXFVCXBFGBCD-QKDMMWSPSA-N
|
|||||
| CAS Number |
CAS 697235-38-4
|
|||||
| Pharmaceutical Properties | Molecular Weight | 654.7 | Topological Polar Surface Area | 172 | ||
| Heavy Atom Count | 47 | Rotatable Bond Count | 11 | |||
| Hydrogen Bond Donor Count | 4 | Hydrogen Bond Acceptor Count | 13 | |||
| XLogP |
1.6
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
CHEBI:66484
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Therapeutic potential of the translation inhibitor silvestrol in hepatocellular cancer. PLoS One. 2013 Sep 26;8(9):e76136. | |||||
| 2 | Resistance to the translation initiation inhibitor silvestrol is mediated by ABCB1/P-glycoprotein overexpression in acute lymphoblastic leukemia cells. AAPS J. 2011 Sep;13(3):357-64. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.